Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 0.61 |
| ▸ | MAPK13 | O15264 | 11/20 | 0.61 |
| ▸ | MAPK12 | P53778 | 11/20 | 0.61 |
| ▸ | MAPK11 | Q15759 | 11/20 | 0.61 |
| ▸ | GCGR | P47871 | 6/20 | 0.61 |
| ▸ | CSNK1D | P48730 | 5/20 | 0.61 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.61 |
| ▸ | MAPK9 | P45984 | 4/20 | 0.61 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.61 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.61 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.61 |
| ▸ | FRK | P42685 | 2/20 | 0.61 |
| ▸ | GSK3B | P49841 | 2/20 | 0.61 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.61 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.61 |
| ▸ | PRKACA | P17612 | 2/20 | 0.61 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.61 |
| ▸ | LCK | P06239 | 1/20 | 0.61 |
| ▸ | RET | P07949 | 1/20 | 0.61 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4584929 | 0.87 | MAPK14 (0.56) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL4586451 | 0.83 | MAPK14 (0.51) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL4585785 | 0.82 | ALOX5 (0.64) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL4553291 | 0.81 | MAPK14 (0.72) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL6471800 | 0.81 | MAPK14 (0.49) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL6525916 | 0.79 | MAPK14 (0.50) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL4586521 | 0.77 | MAPK14 (0.51) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL7208451 | 0.77 | MAPK14 (0.40) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL22170123 | 0.77 | MAPK11 (1.00) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL1388020 | 0.77 | MAPK11 (1.00) | MAPK14MAPK13MAPK12MAPK11GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539121-A4 | METHODS OF PROMOTING OSTEOGENESIS | SCIOS INC (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1545535-A4 | TREATMENT OF PAIN BY INHIBITION OF P38 MAP KINASE | SCIOS INC (US) | 2008-06-04 | — | — | EP | disclosed |
| US-20080108658-A1 | METHODS OF PROMOTING OSTEOGENESIS | PROTTER ANDREW A | 2008-05-08 | — | — | US | disclosed |
| EP-1583535-A4 | METHODS FOR TREATING DIABETES | SCIOS INC (US) | 2008-03-19 | — | — | EP | disclosed |
| US-20080039461-A1 | Treatment of pain by inhibition of p38 map kinase | PROTTER ANDREW A | 2008-02-14 | — | — | US | disclosed |
| US-7268139-B2 | Methods of promoting osteogenesis | SCIOS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-7244441-B2 | Stents and intra-luminal prostheses containing map kinase inhibitors | SCIOS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1676574-A2 | Methods for promoting survival of transplanted tissues and cells | Johnson & Johnson Vision Care, Inc. (US) | 2006-07-05 | — | — | EP | disclosed |
| US-20060019971-A1 | Treatment of cardiovascular disease with inhibitors of p38 kinase | SCIOS INC. | 2006-01-26 | — | — | US | disclosed |
| EP-1583535-A2 | METHODS FOR TREATING DIABETES | SCIOS INC. (US) | 2005-10-12 | — | — | EP | disclosed |
| WO-2004019873-A9 | METHODS OF PROMOTING OSTEOGENESIS | SCIOS INC (US) | 2004-06-24 | — | — | WO | disclosed |
| US-20040122008-A1 | Treatment of pain by inhibition of p38 MAP kinase | SCIOS, INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2004053107-A2 | METHODS FOR TREATING DIABETES | SCIOS INC. (US) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004024083-A2 | METHODS OF BONE HEALING | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2004-03-25 | — | — | WO | disclosed |
| WO-2004021988-A2 | TREATMENT OF PAIN BY INHIBITION OF P38 MAP KINASE | SCIOS INC. (US) | 2004-03-18 | — | — | WO | disclosed |
| WO-2004019873-A2 | METHODS OF PROMOTING OSTEOGENESIS | SCIOS INC. (US) | 2004-03-11 | — | — | WO | disclosed |
| US-6610695-B1 | Prophylaxis or treatment of CSBP/RK/p38 kinase mediated disease | SMITHKLINE BEECHAM CORPORATION | 2003-08-26 | — | — | US | disclosed |
| EP-0994870-A4 | NOVEL ARYLOXY SUBSTITUTED PYRIMIDINE IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM (US) | 2002-10-23 | — | — | EP | disclosed |
| EP-0994870-A1 | NOVEL ARYLOXY SUBSTITUTED PYRIMIDINE IMIDAZOLE COMPOUNDS | Smithkline Beecham (US) | 2000-04-26 | — | — | EP | disclosed |
| WO-1998057966-A1 | NOVEL ARYLOXY SUBSTITUTED PYRIMIDINE IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019971-A1 | Treatment of cardiovascular disease with inhibitors of p38 kinase | MAPKAPK5, MAPK1, MAPKAPK2 | MAPK14 36/4885MAPK13 34/4885MAPK12 27/4885 |
| US-20080108658-A1 | METHODS OF PROMOTING OSTEOGENESIS | MAPK1, BMP2, MAPK3 | MAPK14 23/4885MAPK13 15/4885MAPK12 30/4885 |
| US-20040122008-A1 | Treatment of pain by inhibition of p38 MAP kinase | OPRK1, OPRL1, MAPK3 | MAPK14 36/4885MAPK13 39/4885MAPK12 28/4885 |
| US-20080039461-A1 | Treatment of pain by inhibition of p38 map kinase | OPRK1, OPRL1, MAPK3 | MAPK14 36/4885MAPK13 39/4885MAPK12 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.